◎ Sugi Atlas

Atlas / Disease / Heparin-induced thrombocytopenia

Heparin-induced thrombocytopenia

disease
On this page

Also known as HATheparin-associated thrombocytopeniaheparin-induced thrombocytopenia (disease)heparin-induced thrombocytopenia type 2HIT

Summary

Heparin-induced thrombocytopenia (MONDO:0018048) is a disease and 40 clinical trials. Top therapeutic interventions include fondaparinux, argatroban, and bivalirudin. A subtype of thrombotic disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Prevalence: Unknown (Worldwide)
  • Phenotypes (HPO): 15
  • Clinical trials: 40

Clinical features

Signs & symptoms

Clinical features (HPO)

15 HPO clinical features (Orphanet curated; top 15 by frequency):

HPO IDTermFrequency
HP:0001907ThromboembolismVery frequent (80-99%)
HP:0001973Autoimmune thrombocytopeniaVery frequent (80-99%)
HP:0100724HypercoagulabilityVery frequent (80-99%)
HP:0002625Deep venous thrombosisFrequent (30-79%)
HP:0003144Increased serum serotoninFrequent (30-79%)
HP:0004420Arterial thrombosisFrequent (30-79%)
HP:0004936Venous thrombosisFrequent (30-79%)
HP:0001297StrokeOccasional (5-29%)
HP:0001658Myocardial infarctionOccasional (5-29%)
HP:0002204Pulmonary embolismOccasional (5-29%)
HP:0002637Cerebral ischemiaOccasional (5-29%)
HP:0005521Disseminated intravascular coagulationOccasional (5-29%)
HP:0012649Increased inflammatory responseOccasional (5-29%)
HP:0030248Mesenteric venous thrombosisOccasional (5-29%)
HP:0040231Abnormal onset of bleedingVery rare (<1-4%)

Identifiers

Disease identifiers

FieldValue
Canonical nameheparin-induced thrombocytopenia
Mondo IDMONDO:0018048
Orphanet3325
ICD-111143142333
SNOMED CT73397007
UMLSC0272285
MedGen124423
GARD0002650
MedDRA10062506
Is cancer (heuristic)no

Also known as: HAT · heparin-associated thrombocytopenia · heparin-induced thrombocytopenia · heparin-induced thrombocytopenia (disease) · heparin-induced thrombocytopenia type 2 · HIT

Data availability: 1 HPO phenotype.

Disease family

This is a subtype of thrombotic disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › thrombotic disease › heparin-induced thrombocytopenia

Related subtypes (7): marantic endocarditis, portal vein thrombosis, intracranial thrombosis, coronary thrombosis, acquired purpura fulminans, isolated splenic vein thrombosis, isolated mesenteric vein thrombosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 40.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified23
PHASE35
PHASE25
PHASE44
PHASE13

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00196417PHASE4UNKNOWNThe HIT-TRAP Trial
NCT00603824PHASE4WITHDRAWNFondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT)
NCT00759083PHASE4WITHDRAWNBivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients
NCT00798525PHASE4TERMINATEDArgatroban Versus Lepirudin in Critically Ill Patients
NCT00043940PHASE3COMPLETEDAnticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning)
NCT00198588PHASE3COMPLETEDEfficacy and Safety Study of Argatroban to Treat Heparin-Induced Thrombocytopenia
NCT01598168PHASE3TERMINATEDRivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia
NCT03147638PHASE3UNKNOWNMulti-Center Single Arm Trial to Determine The Effectiveness of Warfarin Therapy Duration For Heparin-Induced Thrombocytopenia (HIT)
NCT03809481PHASE3TERMINATEDOpen-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban
NCT00673439PHASE2TERMINATEDFondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)
NCT00861692PHASE2COMPLETEDClinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II
NCT02501434PHASE2SUSPENDEDAneurysmal Subarachnoid Hemorrhage Trial RandOmizing Heparin
NCT03594045PHASE2TERMINATEDEfficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)
NCT05785819PHASE2TERMINATEDA Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia
NCT00412464PHASE1COMPLETEDPilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis
NCT00489437PHASE1COMPLETEDHeparin-Induced Thrombocytopenia Score Card Study
NCT05325346PHASE1COMPLETEDA Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects
NCT02717039Not specifiedRECRUITINGPharmacogenomics of Heparin-Induced Thrombocytopenia
NCT06033300Not specifiedRECRUITINGCharacterization and Quantification of Platelet/Leukocyte Aggregates in Patients With Suspected Heparin-induced Thrombocytopenia
NCT00198575Not specifiedUNKNOWNA Study on the Prevalence of Heparin-Induced Thrombocytopenia in Cardiovascular Patients
NCT00283322Not specifiedCOMPLETEDHeparin Antibodies in Intensive Care Unit Patients (HAICU)
NCT00456001Not specifiedCOMPLETEDHeparin Induced Thrombocytopenia: Pharmacoeconomics
NCT00456326Not specifiedCOMPLETEDHeparin-Induced Thrombocytopenia Registry
NCT00748839Not specifiedCOMPLETEDHeparin-Induced Thrombocytopenia: Development and Validation of a Predictive Clinical
NCT00946400Not specifiedUNKNOWNValidating 4Ts for Heparin Induced Thrombocytopenia (HIT)
NCT01102790Not specifiedUNKNOWNGeneration of Heparin-induced Thrombocytopenia (HIT)-Antibodies Without Prior Heparin Exposure
NCT01178333Not specifiedCOMPLETEDHeparin-Induced Thrombocytopenia - Retrospective Analysis of Data on Incidence and Outcomes Study
NCT01654848Not specifiedCOMPLETEDHeparin-induced Thrombocytopenia (HIT II) in Liver Transplant Recipients
NCT02526485Not specifiedCOMPLETEDImmunogenetics of Heparin-Induced Thrombocytopenia: Aim 2
NCT02790567Not specifiedCOMPLETEDRapid Diagnosis of Heparin-Induced Thrombocytopenia in Surgical Critically Ill Patients
NCT03148912Not specifiedUNKNOWNOptimizing the Diagnosis of Heparin Induced Thrombocytopenia
NCT03269019Not specifiedUNKNOWNThrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia
NCT03979625Not specifiedCOMPLETEDPrognosis Related to Induced Thrombopenia With Heparin Under Venoarterial ECMO in Reanimation
NCT04751357Not specifiedUNKNOWNArgatroban Monitoring in Critically Ill Patients: Evaluation of a Novel Ecarin-based Bedside Test
NCT04782843Not specifiedUNKNOWNEvaluation of the Intra-observer Agreement of the HEP Score in Surgical Intensive Care.
NCT04842760Not specifiedUNKNOWNPLATELET Function Assay With Flow Imaging on ImageSTREAM Cytometer
NCT05586854Not specifiedUNKNOWNMulticenter Study on Dialysis Modalities for End-stage Chronic Renal Failure Patients With Heparin-induced Thrombocytopenia
NCT05783895Not specifiedUNKNOWNComparison of Pre-test Probability Model for Heparin-induced Thrombocytopenia in Post-operative Cardiac Surgery
NCT06066762Not specifiedUNKNOWNArgatroban Monitoring in Acute Suspected Heparin-induced Thrombocytopenia.
NCT06180785Not specifiedUNKNOWNPerformance Evaluation of the Biological Diagnosis of HIT

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
FONDAPARINUX49
ARGATROBAN45
BIVALIRUDIN42
DANAPAROID SODIUM41
LEPIRUDIN41
RIVAROXABAN41
VLX-100522
CHEMBL50201605
CHEMBL5946105
CHEMBL127625803

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 21

This page pulls from 21 datasets indexed by BioBTree:

chembl_moleculecivic_evidenceclinical_trialsclinvarefogardgenccgwasgwas_studyhgncicd11meddramedgenmeshmimmondomondochildmondoparentorphanetsctidumls